Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Does moderate wine consumption affect lipitor's strength?Can you provide a breakdown of yervoy's discounted cost?Is aspirin's onset of headache relief faster or slower than new antiplatelets?Does lipitor's effectiveness depend on meals?Can you provide a breakdown of yervoy's discounted cost?
See the DrugPatentWatch profile for Cosentyx
When do Biosimilars Enter the Market? The patent for Cosentyx, a biologic medication used to treat psoriasis, plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis, is set to expire in 2028 ([1] DrugPatentWatch.com). This means that in 2028 and possibly before if patent disputes are settled, the market will open up for biosimilar versions of Cosentyx. Who Makes the Alternatives? Several companies, including Amgen and Sandoz, are developing biosimilars to Cosentyx (secukinumab) ([2] Clinical Trials.gov). These biosimilars will be made using the same active ingredients and have a similar molecular structure to Cosentyx, but may not be identical in all aspects. Differences between Biosimilars and Brand Name Drugs While biosimilars have the same primary and secondary structure, post-translational modifications, purity, and potency as the reference product, there can be small differences in things like host cell lines, fermentation procedures, and final formulation ([3] Wikipedia). Pricing and Availability Biosimilars are generally expected to be around 15-30% cheaper than the reference product, as they don't have to recoup research and development costs paid by the brand-name company ([4] Biosimilars Council). However, prices may vary depending on the manufacturer and the country in which they are sold. Regulatory Status Biosimilars must undergo rigorous testing and approval by regulatory agencies such as the FDA before they can enter the market. This includes clinical trials to demonstrate similar efficacy and safety compared to the brand-name product ([5] FDA.gov). Timeline for Biosimilar Entry The exact timeline for the introduction of biosimilars will depend on various factors, including patent disputes, regulatory approval, and market demand. Sources: [1] https://drugpatentwatch.com/listings/secukinumab [2] https://clinicaltrials.gov/ct2/results?cond=&term=secukinumab+AND+biosimilar&cntry=&state=&city=&dist= [3] https://en.wikipedia.org/wiki/Biosimilar#Differencesbetweenbiosimilarsandreference_products [4] https://biosimilarscouncil.org/patient-affordability [5] https://www.fda.gov/drugs/development-approval-process-drugs/biosimilars-cbdt-1
Other Questions About Cosentyx :